Cervical Cancer Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Cervical Cancer Pipeline Insight 2024" report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Cervical Cancer Pipeline Report
• Over 70+ Cervical Cancer companies are evaluating 70+ Cervical Cancer pipeline therapies in various stages of development, and their anticipated acceptance in the Cervical Cancer market would significantly increase market revenue.
• The leading Cervical Cancer Companies working in the market include Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, Akeso Biopharma, AnGes, Advenchen Laboratories/Jiangsu ChiaTai Tianqing Pharmaceutical, Xiamen Innovax Biotech, Genentech, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, EMD Serono, Merck, and others.
• Promising Cervical Cancer Pipeline Therapies in the various stages of development include M7824, Carboplatin, Paclitaxel, Tisotumab Vedotin, topotecan, and others.
• April 2024: John Diaz announced a study of Phase 2 clinical trials for pembrolizumab and olaparib. The study is a non-randomized, open-label phase II clinical trial to test the investigational combination of the drug pembrolizumab with the drug olaparib in patients diagnosed with advanced or recurrent cervical carcinoma after standard chemotherapy.
• April 2024: Seagen Inc. announced a study of Phase 3 clinical trials for tisotumab vedotin, topotecan, vinorelbine, and gemcitabine. This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent).

Request a sample and discover the recent breakthroughs happening in the Cervical Cancer Pipeline landscape @ Cervical Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Cervical Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Cervical Cancer NDA approvals (if any), and product development activities comprising the technology, Cervical Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Cervical Cancer Overview
Cervical cancer remains the fourth most common cancer in developing countries. It develops in a woman's cervix (the entrance to the uterus from the vagina) and happens when the cells on your cervix begin to change to precancerous cells. Not all precancerous cells will turn to cancer, but finding these problematic cells and treating them before they can change is critical to preventing cervical cancer.

Find out more about Cervical Cancer Therapeutics Assessment @ Cervical Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cervical Cancer Emerging Therapies Profile

Axalimogene filolisbac: Advaxis
Axalimogene filolisbac is a type of cancer vaccine being developed as immunotherapy that attacks HPV-associated cancers such as cervical cancers. It works by alerting the body's immune system to the presence of cancer, stimulating the body's natural defenses to attack the cancer. Axalimogene filolisbac is given intravenously and is being developed for the treatment of persistent, recurrent, or metastatic, squamous or non-squamous cell cervical cancer in patients who progress beyond first-li Phase III Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV ne therapy. If licensed, Axalimogene filolisbac will offer a new treatment option for this patient group.

Camrelizumab: Jiangsu HengRui Medicine Co., Ltd.
Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer. The drug is currently being evaluated in Phase III clinical trial for the treatment of cervical cancer.

AK104: Akeso
Cadonilimab (AK104) is a novel, potential next-generation, first-in-class bi-specific PD-1/CTLA-4 immuno-oncology backbone drug independently developed by the Company, and its major indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell cancer and nasopharyngeal carcinoma. The preliminary research data of cervical cancer, gastric cancer and other tumors shows that, as compared with the combination therapy of PD-1 and CTLA-4, Cadonilimab has much lower toxicity and demonstrated promising safety profile and efficacy. In September 2020, National Medical Products Administration (the NMPA) of China has officially accepted the new drug application for the world's first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody, research and development code: AK104) for the treatment of relapsed or metastatic cervical cancer, which has received priority review.

Durvalumab :AstraZeneca
A drug that binds to the protein PD-L1 to help immune cells kill cancer cells better and is used to treat different types of cancer. Durvalumab is used alone or with other drugs to treat adults with certain types of extensive-stage small cell lung cancer or stage III non-small cell lung cancer. It is also being studied in the treatment of other types of cancer. Durvalumab may block PD-L1 and help the immune system kill cancer cells. It is a type of monoclonal antibody and a type of immune checkpoint inhibitor. A Phase III clinical trial is being conducted for durvalumab to treat patients with cervical cancer.

HLX10:Shanghai Henlius Biotech
HLX10, a novel recombinant humanised anti-programmed cell death protein 1 (PD-1) mAb independently developed by Henlius, has the potential to treat a variety of solid tumours. HLX10 has exhibited better pharmacokinetics, pharmacodynamics properties, favourable safety, tolerability profile and anti-tumor activity in preclinical and early clinical research studies. It is currently being investigated in Phase II stage of development to provide the potential treatment for cervical cancer.

Cervical Cancer Therapeutics Assessment
There are approx. 70+ key Cervical Cancer companies which are developing the therapies for Cervical Cancer. The Cervical Cancer companies which have their Cervical Cancer drug candidates in the most advanced stage, i.e. phase III include, Advaxis.

DelveInsight's Cervical Cancer pipeline report covers around 70+ products under different phases of clinical development like
• Late stage products (Phase III)Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Cervical Cancer Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Learn more about the emerging Cervical Cancer Pipeline Therapies @ Cervical Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Cervical Cancer Pipeline Report
• Coverage- Global
• Cervical Cancer Companies- Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, Akeso Biopharma, AnGes, Advenchen Laboratories/Jiangsu ChiaTai Tianqing Pharmaceutical, Xiamen Innovax Biotech, Genentech, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, EMD Serono, Merck, and others.
• Cervical Cancer Pipeline Therapies- M7824, Carboplatin, Paclitaxel, Tisotumab Vedotin, topotecan, and others.
• Cervical Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

Dive deep into rich insights for drugs for Cervical Cancer Pipeline Companies and Therapies, click here @ Cervical Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Cervical Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Cervical Cancer - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Axalimogene filolisbac : Advaxis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II/III)
11. QL 1604: Qilu Pharmaceutical
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. NP 137: Netris Pharma
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. RTX 321: Rubius Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Cervical Cancer Key Companies
21. Cervical Cancer Key Products
22. Cervical Cancer- Unmet Needs
23. Cervical Cancer- Market Drivers and Barriers
24. Cervical Cancer- Future Perspectives and Conclusion
25. Cervical Cancer Analyst Views
26. Cervical Cancer Key Companies
27. Appendix

Got Queries? Find out the related information on Cervical Cancer Mergers and acquisitions, Cervical Cancer Licensing Activities @ Cervical Cancer Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.